Camrelizumab and apatinib show higher response rates and survival in treatment-naive patients with ESCC
Treatment Naive Patients Show Better Survival with Camrelizumab and Apatinib
This meta-analysis evaluates the efficacy of camrelizumab plus apatinib for advanced or metastatic esophageal squamous cell carcinoma. The a…
Patients with advanced esophageal cancer who have not had prior treatment may see better survival rates when using a combination of camreliz…
Sintilimab may trigger autoimmune GFAP astrocytopathy in esophageal squamous cell carcinoma patients
New cancer treatment may cause rare brain inflammation in patients
This case report and literature review describes a patient with advanced esophageal squamous cell carcinoma who developed autoimmune GFAP as…
A new type of immunotherapy for esophageal cancer can trigger a rare brain condition, requiring doctors to watch for early signs of neurolog…
Neoadjuvant chemoimmunotherapy improves pathological response and surgical rates in resectable esophageal squamous cell carcinoma
Immune therapy shows promise for esophageal squamous cell carcinoma
This meta-analysis of randomized controlled trials involving 1070 patients found that neoadjuvant chemoimmunotherapy (NIC) significantly imp…
Adding immune checkpoint inhibitors to chemotherapy before surgery significantly improves tumor response rates in patients with esophageal c…
High PTTG1 expression correlates with poorer survival and advanced disease in various solid tumors
High levels of PTTG1 protein linked to worse cancer outcomes
This meta-analysis of 22 studies from 21 articles analyzed the prognostic value of PTTG1 expression across multiple solid tumors. High PTTG1…
A review of 22 studies shows that high levels of the PTTG1 protein are linked to shorter survival times in several types of solid tumors.
Robot-assisted oesophagectomy shows non-inferior survival in oesophageal squamous cell carcinoma
Robot-assisted surgery may improve survival for oesophageal cancer patients
A randomised trial compared robot-assisted versus thoracoscopic oesophagectomy for resectable oesophageal squamous cell carcinoma. The autho…
A large trial found robot-assisted oesophagectomy linked to higher five-year survival than thoracoscopic surgery for oesophageal squamous ce…
Meta-analysis finds sex-based differences in ICI survival benefit for advanced gastroesophageal cancer
Immunotherapy Works Differently for Men and Women with Stomach Cancer
This meta-analysis of 15 RCTs examined immune-checkpoint inhibition for advanced gastroesophageal cancer. It found a significant overall sur…
Men with esophageal cancer gain a clear survival edge from immunotherapy, while women do not, but both sexes benefit similarly in stomach ca…
Meta-analysis shows neoadjuvant chemoradiation improves resection and survival outcomes for esophageal squamous cell carcinoma patients compared to chemotherapy alone
Adding radiation before surgery helps some esophageal cancer patients get better surgery results and live longer
This meta-analysis of 2,174 patients reveals that adding radiation to chemotherapy significantly boosts resection rates and survival for squ…
A large review found that adding radiation to chemotherapy before surgery helped remove more tumors in certain cancer types. This approach a…
GERD Associated with Increased Risk of Laryngeal Cancer in Meta-Analysis
Large study links GERD to higher risk of laryngeal cancer
A systematic review and meta-analysis of 1,768,394 adults found that gastroesophageal reflux disease (GERD) was significantly associated wit…
A massive analysis of nearly 1.8 million adults found a link between gastroesophageal reflux disease and increased risk of laryngeal cancer.
SIB-RT plus S-1 improves survival in elderly inoperable esophageal cancer
Combination therapy improves survival in older esophageal cancer patients
This phase III multicenter RCT compared simultaneous integrated boost radiotherapy plus oral S-1 (CRTCT) to radiotherapy alone in patients a…
Adding chemo to radiation boosts 5-year survival from 24% to 34% in older patients with inoperable esophageal cancer.
Review of multimodal deep learning model for esophageal squamous cell carcinoma diagnosis
New AI tool spots esophageal cancer early with expert accuracy
This review synthesizes a model development and validation study for esophageal squamous cell carcinoma.
A new AI system matches expert doctors in spotting early esophageal cancer. This could change how patients get diagnosed.
Deep learning segmentation with CT elasticity features predicts right recurrent laryngeal nerve metastasis in esophageal cancer
AI Can Spot Hidden Cancer Spread in the Neck Before Surgery
This retrospective cohort study of 415 patients with esophageal squamous cell carcinoma evaluated a deep learning-based segmentation model w…
This research could help surgeons avoid damaging a vital nerve during esophageal cancer surgery, making operations safer and more precise.
Neoadjuvant Chemoimmunotherapy Alters Tumor Microenvironment in Esophageal Cancer
Combination therapy may help overcome resistance in esophageal cancer
This Phase 3 RCT in 55 patients with locally advanced esophageal squamous cell carcinoma compared neoadjuvant chemotherapy alone versus comb…
A small trial suggests combination therapy might help overcome resistance in esophageal cancer by targeting specific immune cells.
Research across Head and Neck Cancer
Related studies from across the Head and Neck Cancer family.
Lenvatinib plus pembrolizumab did not improve overall survival compared to standard of care
Trial shows lenvatinib and pembrolizumab do not improve survival
This Phase 2 randomized trial evaluated lenvatinib and pembrolizumab in 374 adults with recurrent or metastatic head and neck squamous cell …
A Phase 2 trial found that a combination of lenvatinib and pembrolizumab did not improve overall survival for patients with advanced head an…
High tumor mutational burden correlates with improved objective response rate in HNSCC patients
High tumor mutation burden predicts better results in head cancer
This meta-analysis of 1472 patients with head and neck squamous cell carcinoma (HNSCC) found that high tumor mutational burden (TMB) is asso…
A high number of mutations in a tumor may help doctors predict which patients will respond best to immunotherapy.
Combination Therapies Improve Progression Free Survival in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Combination therapies show promise for advanced head and neck cancer
This meta-analysis evaluated combination therapies involving targeted agents or immunotherapy with chemotherapy for patients with recurrent …
Combining immunotherapy or targeted drugs with chemotherapy may help patients with advanced head and neck cancer live longer without the dis…
HPV shows strong association with oropharyngeal SCC while other oncogenic viruses show limited evidence
Viruses linked to oral and throat cancers in new review
This systematic review examines the role of various oncogenic viruses in oral and oropharyngeal squamous cell carcinomas. It identifies a co…
A strong link between HPV and throat cancer is confirmed, while other viruses show less clear evidence of causing cancer.
Hyperspectral imaging shows strong diagnostic performance for oral cancer detection in scoping review
Hyperspectral imaging shows promise for detecting oral cancer
This scoping review of 15 studies found that hyperspectral imaging (HSI) demonstrates strong diagnostic performance for detecting and charac…
A new review finds hyperspectral imaging can spot oral cancer with high accuracy, offering a non-contact alternative for margin assessment.
Early recognition of femoral metastasis in HNSCC is essential to facilitate timely palliative intervention
New data reveals management of head and neck cancer spread
This systematic review characterizes clinical features and management outcomes for patients with head and neck squamous cell carcinoma (HNSC…
Identifying how head and neck cancer spreads to the femur can help doctors provide better care and improve quality of life for patients.
Pretreatment CPS and HPV status correlate with pathological response in neoadjuvant immunotherapy for LAHNSCC
Certain markers may predict how well immunotherapy treats head cancer
This meta-analysis of 26 studies involving 980 patients with locally advanced head and neck squamous cell carcinoma (LAHNSCC) found that hig…
New data suggests that specific biological markers can help doctors predict how well a patient's tumor will respond to immunotherapy.
Oral diseases stem from disrupted host-microbiome-immune balance, narrative review argues
New research explores how oral bacteria drive gum disease
This narrative review argues that periodontitis, dental caries, and oral squamous cell carcinoma should be understood as disorders of host-m…
Oral health depends on a delicate balance between your immune system, tissue barriers, and the trillions of microbes living in your mouth.
HOX gene dysregulation influences cellular processes but currently lacks utility as reliable HNSCC biomarkers
HOX genes play complex roles in head and neck cancer
This mini-review examines the role of HOX genes in head and neck squamous cell carcinoma (HNSCC). The authors conclude that while these gene…
New research highlights how HOX genes drive tumor growth and survival in head and neck cancers, though their use as clinical tools is still …
Local brain therapies associated with reduced mortality in HNSCC patients with brain metastasis
Local brain treatments linked to modest survival gains in rare head and neck cancer cases
This retrospective cohort analysis evaluated 201 patients with head and neck squamous cell carcinoma and brain metastasis from three tertiar…
Local brain treatments linked to lower death risk for rare head and neck cancer patients who develop brain metastases, though most still die…
Fianlimab plus cemiplimab showed objective response rates of 20% to 33% in advanced solid tumors during a Phase 1 study.
Early trial shows new cancer drug combo helps some patients with advanced disease
This Phase 1, first-in-human dose-expansion study evaluated fianlimab 1600 mg plus cemiplimab 350 mg in patients with advanced non-small cel…
A new drug combination helped some patients with advanced lung, kidney, head and neck, or skin cancer shrink their tumors in early testing.
Molecular markers may improve risk assessment in oral potentially malignant disorders
Molecular tools may improve risk assessment for oral lesions
This narrative review examines the limitations of conventional histopathological grading for oral potentially malignant disorders (OPMDs) an…
A review suggests molecular methods could better assess risk for oral potentially malignant disorders where standard grading is unreliable.
Questions about Esophageal Squamous Cell Carcinoma
How does neoadjuvant chemoimmunotherapy change the tumor environment in esophageal squamous cell carcinoma?
Neoadjuvant chemoimmunotherapy remodels the tumor microenvironment in ESCC by increasing cytotoxic CD8+ T cells, dendritic cell remodeling, and reducing tumor volume, which correlates with better pathological response and survival.
Full answer →Does gastroesophageal reflux disease increase the risk of laryngeal cancer or esophageal squamous cell carcinoma?
GERD increases the risk of laryngeal cancer but not esophageal squamous cell carcinoma, according to a large meta-analysis.
Full answer →Is S-1 medication better than radiation alone for elderly patients with esophageal squamous cell carcinoma?
Yes, S-1 plus radiation improves survival over radiation alone for elderly patients with inoperable esophageal squamous cell carcinoma, based on a phase III trial.
Full answer →Can a deep learning model help diagnose esophageal squamous cell carcinoma more accurately?
Yes, deep learning models can help diagnose esophageal squamous cell carcinoma more accurately, with studies showing high AUC values for tumor detection and lymph node metastasis prediction.
Full answer →Does adding radiation to chemotherapy help esophageal squamous cell carcinoma patients live longer?
Adding radiation to chemotherapy before surgery does not clearly improve overall survival for esophageal squamous cell carcinoma patients compared to chemotherapy alone, but it increases the chance of a complete tumor response.
Full answer →All Esophageal Squamous Cell Carcinoma Articles
- Camrelizumab and apatinib show higher response rates and survival in treatment-naive patients with ESCC
- Sintilimab may trigger autoimmune GFAP astrocytopathy in esophageal squamous cell carcinoma patients
- Neoadjuvant chemoimmunotherapy improves pathological response and surgical rates in resectable esophageal squamous cell carcinoma
- High PTTG1 expression correlates with poorer survival and advanced disease in various solid tumors
- Robot-assisted oesophagectomy shows non-inferior survival in oesophageal squamous cell carcinoma
- Meta-analysis finds sex-based differences in ICI survival benefit for advanced gastroesophageal cancer
- Meta-analysis shows neoadjuvant chemoradiation improves resection and survival outcomes for esophageal squamous cell carcinoma patients compared to chemotherapy alone
- Review of multimodal deep learning model for esophageal squamous cell carcinoma diagnosis
- SIB-RT plus S-1 improves survival in elderly inoperable esophageal cancer
- GERD Associated with Increased Risk of Laryngeal Cancer in Meta-Analysis
- Deep learning segmentation with CT elasticity features predicts right recurrent laryngeal nerve metastasis in esophageal cancer
- Neoadjuvant Chemoimmunotherapy Alters Tumor Microenvironment in Esophageal Cancer
- Timing of surgery after neoadjuvant chemoimmunotherapy impacts survival in operable esophageal squamous cell carcinoma
- PD-1 inhibitors + chemo improve OS, PFS, ORR in first-line advanced ESCC; benefit limited in PD-L1 CPS <1